-
Chardan Downgrades Regeneron Pharmaceuticals, Notes Valuation Concerns
Monday, August 31, 2015 - 1:31pm | 362Read More...Gbola Amusa, Chardan Capital Markets' head of healthcare research, commented in a note on Monday that investors should be "more selective" in the biotech space. As such, the analyst downgraded shares of Regeneron Pharmaceuticals Inc (NASDAQ: REGN) to Neutral from Buy with an unchanged $565 price...
-
FDA Panel Clears Product Path For Sanofi, Regeneron Pharmaceuticals
Wednesday, June 10, 2015 - 10:52am | 316Read More...A key regulatory advisory panel recommended approval of a cholesterol treatment under joint development by Sanofi SA (ADR) (NYSE: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN), the companies said Wednesday. A final ruling is expected July 24 from the Food and Drug Administration,...
-
UPDATE: Barclays Initiates Coverage On Regeneron
Tuesday, January 6, 2015 - 12:28pm | 200Read More...Geoffrey Meacham of Barclays initiated coverage of Regeneron Pharmaceuticals Inc (NASDAQ: REGN) on Tuesday with an Equal-Weight rating and $450 price target as approval and modest growth profile of key drugs are already expected by investors. Based on Meacham's survey of 50 U.S....
